For the first time in Piramal Pharma Solutions’ history, the CDMO’s revenue earned on innovation programs has surpassed that of generic projects.

Over the past five years, innovation revenue has grown from 35% of total revenues to more than 50%, representing a CAGR of 20%. The 50% figure represents work performed for pharma innovator customers across discovery, development and on-patent commercial manufacturing. It includes projects spanning preclinical development through Phases I, II, and III.

“Achieving this threshold is a significant milestone in the history of Piramal Pharma Solutions,” said Peter DeYoung, CEO, Piramal Pharma Solutions. “For many years, our organizational strategies and tactics have focused on building the expertise and capabilities required to fully support innovator work. This breakthrough validates our efforts and secures our position as an innovator CDMO that support customers in their quest to bring new, patient-centric medicines to regulated markets around the world.”

See the company’s financial results for the first quarter ended June 30th, 2024.